Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Broad-spectrum anti-enterovirus protein drug and application thereof

An enterovirus and protein technology, applied in the field of biomedicine, can solve the problem of inability to cross-protect infection, and achieve the effect of simple operation

Pending Publication Date: 2020-04-24
SHANXI JINBO BIO PHARMA CO LTD +1
View PDF7 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] So far, only my country has approved two inactivated vaccines for EV-A71, but this vaccine cannot cross-protect other intestinal infections such as CVA16 and EV-D68
There are no drugs approved for the treatment of enterovirus infection at home and abroad

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Broad-spectrum anti-enterovirus protein drug and application thereof
  • Broad-spectrum anti-enterovirus protein drug and application thereof
  • Broad-spectrum anti-enterovirus protein drug and application thereof

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0055] Methods for preparing formulations known in the art can be found, for example, in "Remington's Pharmaceutical Sciences" (19th Ed.), Ed. A. Gennaro, 1995, Mack Publishing Company, Easton, Pa. Formulations for parenteral administration may, for example, contain excipients, sterile water or saline, poly(alkylene) glycols such as polyethylene glycol, vegetable oils or hydrogenated naphthalenes. Biocompatible, biodegradable lactide polymers, lactide / glycolide copolymers, or polyoxyethylene-polyoxypropylene copolymers can be used to control the release of the compounds. Other potentially useful parenteral delivery systems include ethylene-vinyl acetate copolymer particles, osmotic pumps, implantable infusion systems, and liposomes. Formulations for inhalation may contain excipients such as lactose, or may be aqueous solutions containing, for example, polyoxyethylene-9-lauryl ether, glycocholate and deoxycholate, or may be in the form of nasal drops or Oily solution applied a...

Embodiment 1

[0068] Example 1: Preparation of protein modified by acid anhydride

[0069] 3-hydroxy-phthalic anhydride-modified human serum albumin (3-hydroxyphthalic anhydride-modified human serum albumin, 3HP-HSA) and 3-hydroxy-phthalic anhydride-modified bovine β-lactoglobulin (3- Preparation of hydroxyphthalic anhydride-modified bovine beta-lactoglobulin, 3HP-β-LG):

[0070] (1) Prepare 0.1M disodium hydrogen phosphate, adjust the pH to 8.5, and filter through a 0.2 μm filter membrane to sterilize.

[0071] (2) Dissolve human serum albumin (HSA) and bovine β-lactoglobulin (β-LG) powders in the prepared disodium hydrogen phosphate solution to make the concentration 20 mg / ml.

[0072] (3) Acid anhydrides (3-hydroxy-phthalic anhydride (3HP), maleic anhydride (ML), succinic anhydride (SU)) were dissolved in DMSO to a concentration of 1M.

[0073] (4) An acid anhydride with a final concentration of 12 mM was added to the human serum albumin and bovine β-lactoglobulin solution. Mix immedi...

Embodiment 2

[0081] Example 2: Preparation of proteins with different anhydride modification rates

[0082] (1) Dissolve 20 mg of human serum albumin in 1 ml of 0.1 M disodium hydrogen phosphate solution.

[0083] (2) 3-Hydroxy-phthalic anhydride was dissolved in DMSO to form a 1M mother liquor.

[0084] (3) Add 0mM, 3mM, 6mM, 12mM, 24mM, 48mM and 60mM 3-hydroxy-phthalic anhydride to the human serum albumin solution, respectively.

[0085] (4) Adjust the pH to 8.5-9.0 with 5M sodium hydroxide.

[0086] (5) React at room temperature for 2 hours.

[0087] (6) The modified protein was quantified using the BCA kit of Takara Company. Refer to the manual for specific operations.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
absorbanceaaaaaaaaaa
Login to View More

Abstract

The invention relates to a broad-spectrum anti-enterovirus protein drug and application thereof, and discloses a method for inhibiting growth of enteroviruses and preventing or controlling cells infected with enteroviruses in vitro by acid anhydride modified protein or a composition containing the acid anhydride modified protein. The invention also discloses a biological agent for preventing and treating various enterovirus infections, wherein the biological agent is protein treated by acid anhydride. Specifically, the anhydridized protein is anhydridized human serum albumin and bovine beta lactoglobulin. The proteins can effectively inhibit recent massive outbreak of enterovirus 68 type, enterovirus 71 type and coxsackie virus 16 type infected cells. The inhibitor disclosed by the invention has the advantages of broad-spectrum inhibition of enterovirus invading cells, prevention of virus diffusion, stability, low cost and the like.

Description

technical field [0001] The invention relates to the field of biomedicine, in particular to a broad-spectrum anti-enterovirus protein inhibitor and application thereof. Background technique [0002] Enteroviruses (Enteroviruses, EVs) belong to the family Picornaviridae and belong to the genus Enterovirus. Consists of more than 100 subtypes of viruses. The virus has no envelope and can be divided into 4 subtypes (A, B, C, D). Enteroviruses are distributed worldwide and can cause a wide range of human diseases. Caused diseases range from mild colds and respiratory diseases to severe hand, foot and mouth disease, myocarditis, pancreatitis, meningoencephalitis and polio. In 2014, enterovirus type 68 (EV-D68) broke out on a large scale in the United States and spread globally. In recent years, Enterovirus 71 (EV-A71) and Coxsackievirus 16 (CV-A16) have caused large-scale outbreaks of HFMD every year in the Asia-Pacific region. [0003] EV-D68 has historically rarely caused la...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/38A61K38/17A61P31/14
CPCA61K38/38A61K38/385A61K38/1722A61P31/14A61K2300/00
Inventor 杨霞姜世勃陆路刘泽众
Owner SHANXI JINBO BIO PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com